Skip to content

Applications

Our services have diverse applications that can be useful for many professionals in different fields of knowledge.

Who can benefit from our services?

Our services are aimed at universities, research centers, health professionals, pharmaceutical companies, food companies, and clinical analysis laboratories that develop their activity in the field of metabolic diseases. The applications of our services are diverse:

main applications of Biosfer Teslab services
Figure 1: Main applications

We are an innovative company, specialized in nuclear magnetic resonance, and we seek to provide the best service to our customers. For this reason, we continuously seek partners for national and international projects for the investigation of new markers, analytical methods, new matrices and new treatments that promote the study, prevention, diagnosis and treatment of metabolic disorders in a more careful and accurate way.

Cardiometabolic disease

Changes in the lifestyle of developed and emerging countries favor the exponential appearance of metabolic disorders such as obesity, diabetes, and metabolic syndrome, among others. The appearance of these disorders has drastically increased the number of cardiovascular accidents, placing cardiovascular diseases as the leading cause of death worldwide. According to the World Health Organization, in 2015 there were 17.7 million deaths related to cardiovascular diseases, which accounted for 31% of all deaths worldwide.

cardiovascular system
cholesterol

In this context, the advanced characterization of lipoproteins, glycoproteins and low molecular weight metabolites associated with risk, complemented by the lipid profile, is of great help for the diagnosis and monitoring of pathologies related to disorders of metabolism, allowing the evaluation of the health status of patients with metabolic disorders and inflammatory processes, individuals with a higher risk of developing diabetes and cardiovascular accidents.

Nutritional Interventions

Advanced metabolomic profiling including lipoprotein, glycoprotein, low molecular weight metabolites, as well as lipid families is an excellent tool for nutritional studies, from post-pandrial studies to interventions investigating the relationship between dietary intake and its relationship to health status. The metabolomic study allows us to know the metabolic changes of individuals who have undergone nutritional interventions, both in healthy people and in people suffering from a disease.

nutrition

Cancer

Cancer is the second leading cause of death in Europe, the first among those under 65 years of age. In Spain, more than 200,000 people are diagnosed each year. A timely diagnosis can prevent its development.

For this reason, the study of metabolism for the identification of biomarkers, either for their prevention, for diagnosis, for patient stratification or to follow-up patients, is of great interest in order to acquire new complementary tools for improving people’s health.

cancer
cancer

The advanced characterization of lipoproteins, glycoproteins, low molecular weight metabolites and/or the lipidomic profile are promising tools for the study of inflammatory processes and metabolic alterations in order to obtain metabolic traces, profiles or signatures that characterize the course of cancer. Said tools can be used in biofluids from patients, such as serum, urine or feces, although studies can also be carried out in tissues, either from patients (tumor tissue or primary cultures) or basic studies on cell lines.

Chronic kidney disease

This disease involves a gradual loss of kidney function. The kidneys filter wastes and excess fluids from the blood, which are eliminated through urine. Chronic kidney disease is considered by the World Health Organization as a global public health problem, directly related to diabetes, hypertension and advanced age of the population.

kidney
kidney

In this context, advanced metabolomic characterization including lipoprotein profiling, glycoproteins, low molecular weight metabolites, as well as lipid families is an excellent tool to assess the health status of these patients, with the aim of improving the diagnosis and treatment of the disease beyond traditional markers/tools.

Metabolic disease in fetal growth/infancy

Advanced metabolomic profiling including profiling of lipoproteins, glycoproteins, low molecular weight metabolites, as well as lipid families is an excellent tool to investigate the relationship between mother and baby. Blood or cord blood analysis allows the study of short and long term metabolic effects of the offspring and their correlation with lifelong health. It also allows the study of pregnancy-related complications such as pre-eclampsia and gestational diabetes.

fetal growth

Autoimmune disease

autoimmune disease

Advanced metabolomic profiling that includes profiling of lipoproteins, glycoproteins, low molecular weight metabolites, as well as lipid families. It is an excellent tool to investigate autoimmune diseases. Specifically, this advanced profiling includes both new established markers of chronic inflammation such as GlycA and GlycB, as well as metabolic biomarkers with the aim of improving diagnosis, understanding disease prognosis and/or studying treatments for the disease beyond traditional markers.

ACCIÓ GRANT

BIOSFER TESLAB, SL with the support of ACTION in the frame of the Operative Program FEDER Catalonia 2014-2020 has carried out the “DEVELOPMENT And VALIDATION OF ADVANCED DIAGNOSTIC TEST Of INFLAMMATION And  INSULIN RESISTANCE FOR THE IMPROVEMENT OF  CARDIOVASCULAR RISK USING NUCLEAR MAGNETIC RESONANCE”  (RD15-1-0013).

Biosfer Teslab, along the project, has developed a system of prediction, using of advanced prediction tests, with the aim to improve the evaluation of cardiovascular risk and to identify those individuals with residual cardiovascular risk that would remain undiagnosed with classical risk factors.

In particular, the company has developed a glycoprotein test and a LMWM test - that includes, branched amino acids -, as they have been identified as inflammatory markers and involved in insulin resistance processes, respectively.

The Agency for the Competitiveness of the Company, ACTION, aiding to industrial research centers and experimental development, has granted Biosfer Teslab with an amount of 67,728.97 €.

This aid is programmed in the axis 1, "Boost research, technological development and innovation", specific objective OE 1.2.2, "Transfer and spreading of technology and cooperation between companies and universities or other research centers", line of action "Collaborative R+D projects" under the framework of the FEDER Operational Program of Catalonia 2014-2020